1 / 22

Long term outcomes of patients with l eiomyosarcoma of uterine vs. extra-uterine origin

Long term outcomes of patients with l eiomyosarcoma of uterine vs. extra-uterine origin. Srikanth Divi , Medical Student, Univ. of Pittsburgh Meghan Levy, Kurt Weiss MD, Mark Goodman MD, Richard McGough MD. Background of Leiomyosarcoma (LMS).

joylyn
Download Presentation

Long term outcomes of patients with l eiomyosarcoma of uterine vs. extra-uterine origin

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Long term outcomes of patients with leiomyosarcoma of uterine vs. extra-uterine origin SrikanthDivi, Medical Student, Univ. of Pittsburgh Meghan Levy, Kurt Weiss MD, Mark Goodman MD, Richard McGough MD

  2. Background of Leiomyosarcoma (LMS) • Approximately 10,000 soft tissue sarcomas are diagnosed in the US annually1 • LMS composes up to 10% (1000 cases) and is the third most frequent sarcoma after pleomorphic sarcoma NOS and liposarcoma2 • Classification: • visceral • gastrointestinal, separate from GIST • uterine • somatic • peripheral soft tissues (cutaneous, deep soft tissue) • retroperitoneal (50%) • vascular • bone (rare)

  3. Background of Leiomyosarcoma (LMS) • About 2/3 of retroperitoneal LMS occur in women, median age 60 y • Presenting symptoms nonspecific: abdominal mass, swelling, pain, weight loss, nausea, or vomiting • Presenting size often large (mean size and weight: 16 cm, 1600g) • In contrast, tumors of the extremities affect men and women equally • Significantly smaller (6 cm) than retroperitoneal tumors

  4. Background of Leiomyosarcoma (LMS) • Leiomyomas not necessarily associated with malignant transformation to LMS • Observation that significant number of tumors arise from small blood vessels • LMS also seen in the setting of hereditary retinoblastoma (abnormal Rb1 locus)

  5. Prognosis of patients with somatic soft tissue (SST) LMS • Farshid et al., 42 patients3 (2002) • 8% developed local recurrence, 45% developed mets • Age > 62, size > 4cm, extensive necrosis correlated with metastasis • Conclusion: majority are of vascular origin (39/42 pts), disruption of tumor w/ biopsy is significant RF • Mankin et al., 66 patients4 (2004) • 50% survival at 4.2 years, 62% developed mets • Tumors with greater size (>500 cm3) had 82% mortality rate • Conclusion: presence of mets, size of tumor, MSTS stage effect on survival outcomes

  6. Prognosis of patients with somatic LMS • Scandinavian Sarcoma Group, 225 pts (2006)5 • 10 year survival rate (with localized disease): 49% • Higher grade, larger tumor size, deeper location all significantly correlated with decreased survival • Overall prognosis is poor even with local control (w/ or w/o radiotherapy) • Abraham et al. 115 pts (2012)1 • 1, 5, and 10 year survival: 87%, 57%, 19% • Histological grade, tumor depth, and mets significant predictors of mortality

  7. Prognosis of patients with somatic LMS • Radkowski et al., 65 pts – 20125 • Overall 1, 2, and 5 year survival: 91%, 87%, and 68% • Pts with deep lesions, grade 3 disease, and advanced stage have poorer prognosis

  8. Uterine LMS • Uterine LMS is rare, it accounts for only 1% of all uterine cancers6, however it represents up to 1/3 of all uterine sarcomas • 30-35% of patients have evidence of extra-uterine disease at the time of presentation • 5 year survival for metastatic disease is less than 40% with current therapies • Median age: 50 years, about 10 years older than the median age of presentation for leiomyoma7 • Frequency of incidental LMS detected in women at various ages having surgery for presumed leiomyoma: • 31-40 y: 0.2% • 41-50 y: 0.9% • 51-60 y: 1.4% • 61-81 y: 1.7%

  9. Motivation for study • Does extra-uterine LMS have the same prognosis as uterine LMS? • Some patients with extra-uterine LMS had hysterectomies in the past • Difference in outcomes between those with and those without hysterectomies? • Two distinct disease entities (uterine LMS and extra-uterine LMS) may actually overlap, with patients presenting decades later with recurrences of uterine LMS.

  10. Hypothesis • Patients with uterine LMS have decreased survival compared to extra-uterine LMS • Of patients with extra-uterine LMS, those with prior hysterectomies have decreased survival

  11. Methods • Searched using MARS (Medical Archive Record System) in UPMC system from 1982-present • Surgical pathology reports with designated search terms • Retrieved lists were filtered for correct diagnoses • Diagnosis of extra-uterine LMS • 513 cases of extra-uterine LMS • Included tumors from: GI, cutaneous, peripheral soft tissue, retroperitoneal, vascular, etc. • Diagnosis of uterine LMS • 127 patients

  12. Methods • Patient characteristics identified: • age at diagnosis • tumor characteristics (size, # mitoses, % necrosis, grade, FIGO stage) • metastases • Survival data collected from: • UPMC patient charts (inpatient and outpatient visits) • National and municipal registries • Censored survival data used to construct Kaplan Meier curves

  13. Results

  14. Results

  15. Results – analysis of patients with Extra-uterine LMS • Of the 513 patients with extra-uterine LMS: • 269 were females • 177 with no documentation of hysterectomies • 75 found to have hysterectomies prior to dx of LMS • 17 had hysterectomies after dx of LMS • 75/269 = 27.9% of females with hysterectomies prior to dx of LMS • Differences in survival?

  16. Results – analysis of patients with Extra-uterine LMS

  17. Discussion • Uterine vs. extra-uterine LMS has similar long term outcomes, not statistically significant • Median survival: 4.97 y vs. 4.28 y • HR 1.042, p = 0.74 • Among extra-uterine LMS, those with prior hysterectomies had a longer survival time, not statistically significant • Median: 6.42 y vs. 4.25 y • p = 0.084

  18. Limitations • Population heterogeneity • Does not stratify for commonly used clinical parameters: • Margin status • XRT • Chemotherapy • Other treatments

  19. Conclusion • Retrospective review of 640 cases of LMS • Uterine • Extra-uterine • No difference in long term survival outcomes • Future directions: • Evaluate contribution of clinical parameters • Outcomes of patients with somatic soft tissue LMS

  20. References • Abraham et al. Outcomes and prognostic factors for a consecutive case series of 115 patients with somatic leiomyosarcoma. J Bone Joint Surg Am. 2012 Apr 18; 94(8): 736-44 • O’Sullivan et al. Radiological imaging features of non-uterine leiomyosarcoma. Br J Radiol. 2008 Jan; 81(961): 73-81 • Farshid et al. Leiomyosarcoma of Somatic Soft Tissues. Am J SurgPathol. 2002. 26(1): 14–24. • Mankin et al. Leiomyosarcoma of Somatic Soft Tissues. ClinOrthopRelat Res. 2004 Apr ; (421): 225-31 • Radkowski et al. Leiomyosarcoma of the somatic soft tissues. J SurgOrthop Adv. 2012. 21(2): 96-101 • Leitao et al. Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis. GynecolOncol. 2012 May. 125(2): 409-413

  21. Acknowledgments • Meghan Levy • Alma Heyl – Clinical Research Coordinator • Kurt Weiss, MD and Mark Goodman, MD • Richard McGough, MD – Project Mentor

  22. Thank you

More Related